Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer To the Editor: In the IMpassion130 trial, Schmid et al. (Nov. 29 issue)1 found that combination therapy with atezolizumab plus nanoparticle albumin-bound (nab)–paclitaxel led to longer progression-free survival than placebo plus nab-paclitaxel among patients with metastatic triple-negative breast cancer. The effect was observed both in the intention-to-treat population and in the population of patients with tumors that were positive for programmed death ligand 1 (PD-L1). In this trial, the BRCA mutation profile of the patients was not reported in the published data. It has been widely reported that germline mutations in BRCA1 or BRCA2 cause DNA-repair defects and genomic instability.2 . . . http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The New England Journal of Medicine The New England Journal of Medicine

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

The New England Journal of Medicine, Volume 380 (10): 4 – Mar 7, 2019

Loading next page...
 
/lp/the-new-england-journal-of-medicine/atezolizumab-and-nab-paclitaxel-in-advanced-triple-negative-breast-3bGRkF4PDA
Publisher
The New England Journal of Medicine
Copyright
Copyright © 2019 Massachusetts Medical Society. All rights reserved.
ISSN
0028-4793
eISSN
1533-4406
DOI
10.1056/NEJMc1900150
Publisher site
See Article on Publisher Site

Abstract

To the Editor: In the IMpassion130 trial, Schmid et al. (Nov. 29 issue)1 found that combination therapy with atezolizumab plus nanoparticle albumin-bound (nab)–paclitaxel led to longer progression-free survival than placebo plus nab-paclitaxel among patients with metastatic triple-negative breast cancer. The effect was observed both in the intention-to-treat population and in the population of patients with tumors that were positive for programmed death ligand 1 (PD-L1). In this trial, the BRCA mutation profile of the patients was not reported in the published data. It has been widely reported that germline mutations in BRCA1 or BRCA2 cause DNA-repair defects and genomic instability.2 . . .

Journal

The New England Journal of MedicineThe New England Journal of Medicine

Published: Mar 7, 2019

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off